G9pharma co., LTD reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 0.00001 million. Net loss was KRW 38,618.94 million compared to KRW 37,256.82 million a year ago.

Basic loss per share from continuing operations was KRW 9,468 compared to KRW 10,344 a year ago. Diluted loss per share from continuing operations was KRW 9,468 compared to KRW 10,344 a year ago. Basic loss per share was KRW 9,468 compared to KRW 10,344 a year ago.